adalimumab

The market dominance of Humira may finally be at an end, as payors make dramatic shifts in favor of biosimilars to ...

DECEMBER 12, 2024

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

Inflammatory bowel disease clinical trials are facing headwinds, with challenges in recruitment and trial design.

OCTOBER 22, 2024

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...

SEPTEMBER 5, 2024

The American Gastroenterological Association recently published a guideline on the management of pouchitis and ...

JULY 31, 2024

An estimated 41% of the US population is obese, including 22% of individuals aged 12 to 19 years, while nearly 1 of ...

MAY 10, 2024

Therapeutic strategies employing a combination of advanced therapies are starting to reveal promising outcomes in ...

JANUARY 15, 2024

This month’s report focuses on an important potential new remedy for post-op CD and I provide a word of ...

JUNE 21, 2023

With 2023 poised to be the year of the adalimumab biosimilar wave, a new report focuses on market expansion and ...

JUNE 8, 2023

New FDA approvals of adalimumab biosimilars are bringing more choice to prescribers.

MAY 25, 2023

The first head-to-head trial comparing ustekinumab and adalimumab has found the two drugs are similarly safe and ...

NOVEMBER 12, 2021